

Cancertrack™

**Blood based liquid biopsies for all
solid organ tumors**




LIQUID BIOPSIES

cancertrack™

NON-INVASIVE INTELLIGENT MULTI-COORDINATE

DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA



About Cancertrack™

Cancertrack™ is a non-invasive blood based investigation that detects cell free tumor DNA (ctDNA) and circulating tumor cells (CTCs) with ultra-high precision, specificity and reliability. Cancertrack™ can be used to monitor the disease/recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anesthesia or painful surgical biopsies.

Features of Cancertrack™



Patients unfit for invasive biopsy can still avail benefit of targeted therapies



Addresses problem of tumor heterogeneity



Helps in real-time disease monitoring and tumor evolution tracking




Therapy failure can be detected prior to clinical / radiological disease progression



Gives information about Mutant Allele Frequency (MAF) and molecular residual disease



Helps to know presence of acquired resistance mutations



High sensitivity (94.72%) and specificity (97.88%)



52 genes (SNVs, CNAs, Fusions, and Indels).



Circulating Tumor Cells (CTCs) enumeration



Relevant clinical trials



Simplified report with indications for approved therapies and genomic highlights



Turn around time: 6-8 working days

Gene Analyzed

SNV Genes:

AKT1, ALK, APC, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, NAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SF3B1, SMAD4, SMO, Tp53

Fusion Genes:

ALK, BRAF, ERG, ETV1, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK3, RET, ROS1


CNA Genes:

CCND1, CCND2, CCND3, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, MYC

Suitable for




Every person who has been diagnosed with cancer, for robust molecular profiling and baseline measurement of cell-free tumor DNA before initiation of therapy



Every patient who is in remission / a cancer survivor and needs monitoring




Every patient who is under treatment for cancer



Every patient, who is not responding satisfactorily to 'Standard of Care' therapy

Keeping track of cancer is very critical

Cancer is best managed by a treatment plan that stays one step ahead of the tumor. However, conventional techniques such as imaging or scans can take more than 3 months to detect whether or not the treatment is working or it has failed. That's why, it is important to determine as quickly as possible if the cancer is responding to the therapy or is progressing. This information is now available through Cancertrack™.



FAQ's



How is Cancertrack™ validated?

Cancertrack™ has been validated clinically and the process validation meets and exceeds the claimed sensitivity and specificity. Our laboratory accredited by ISO 9001:2015, ISO 15189:2012 and ISO 27001:2013, besides its compliance to CAP and CLIA. All Cancertrack™ reports are reviewed by our experienced and qualified Molecular Tumour Board comprising of experts in the field. Our counsellors and experts are available for ongoing support.



Why is early detection of molecular dynamics of cancer critical?

The rapid and continuous evolution of the molecular profile of tumors results in tumor heterogeneity, which confers significant survival benefits on the tumor. Cancertrack unravels these molecular features in real time to identify critical signs linked to recurrence or emerging drug resistance as well as novel vulnerabilities, which empowers the treating clinician to avail optimum treatment strategies to intercept such cancers in a timely manner.



How frequently is it necessary to do the test?

Cancertrack™ should ideally be performed at every important milestone at regular intervals in the fight against cancer and especially when the tumor has disappeared from conventional imaging and patient is under follow-up for recurrence monitoring.



What are the limitations of Cancertrack™?

While Cancertrack™ is extremely robust and multidimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.

Sample Requirement :- 15-20 ml blood in Streck® tube

Accreditations for Our Lab in India



Advena Ltd. Tower Business Centre, 2nd Flr.,
Tower Street, Swatar, BKR 4013, Malta

Contact us:

✉ **UK:** enquiries@datarpgx.com • **Germany:** info-eu@datarpgx.com • **India:** response@datarpgx.com

🌐 datarpgx.com

Proprietary Technology, All Intellectual Property Rights Protected under relevant laws.